E
4D Molecular Therapeutics, Inc.
FDMT
$4.28
$0.040.94%
E
Sell
3/13/2025Downgrade
4D Molecular Therapeutics, Inc. (FDMT) was downgraded to E+ from D- on 3/13/2025 due to a large decline in the solvency index, total return index and growth index. Total revenue declined 66.67% from $3 to $1, operating cash flow declined 56.04% from -$29.39M to -$45.86M, and the quick ratio declined from 17.03 to 14.58.
4D Molecular Therapeutics, Inc. (FDMT) was downgraded to E+ from D- on 3/13/2025 due to a large decline in the solvency index, total return index and growth index. Total revenue declined 66.67% from $3 to $1, operating cash flow declined 56.04% from -$29.39M to -$45.86M, and the quick ratio declined from 17.03 to 14.58.
D
Sell
11/15/2024Upgraded
4D Molecular Therapeutics, Inc. (FDMT) was upgraded to D- from E+ on 11/15/2024 due to an increase in the valuation index.
4D Molecular Therapeutics, Inc. (FDMT) was upgraded to D- from E+ on 11/15/2024 due to an increase in the valuation index.
E
Sell
10/22/2024Downgrade
4D Molecular Therapeutics, Inc. (FDMT) was downgraded to E+ from D- on 10/22/2024 due to a decline in the volatility index and total return index.
4D Molecular Therapeutics, Inc. (FDMT) was downgraded to E+ from D- on 10/22/2024 due to a decline in the volatility index and total return index.
D
Sell
3/14/2023Downgrade
4D Molecular Therapeutics, Inc. (FDMT) was downgraded to D- from D on 03/14/2023.
4D Molecular Therapeutics, Inc. (FDMT) was downgraded to D- from D on 03/14/2023.
D
Sell
2/23/2023Upgraded
4D Molecular Therapeutics, Inc. (FDMT) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index and volatility index.
4D Molecular Therapeutics, Inc. (FDMT) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index and volatility index.
D
Sell
2/8/2023Downgrade
4D Molecular Therapeutics, Inc. (FDMT) was downgraded to D- from D on 2/8/2023 due to a decline in the valuation index.
4D Molecular Therapeutics, Inc. (FDMT) was downgraded to D- from D on 2/8/2023 due to a decline in the valuation index.
D
Sell
11/11/2022Upgraded
4D Molecular Therapeutics, Inc. (FDMT) was upgraded to D from D- on 11/11/2022 due to an increase in the growth index, total return index and volatility index. Total revenue increased 208.64% from $162 to $500, earnings per share increased from -$0.8689 to -$0.7933, and EBIT increased 6.79% from -$28.43M to -$26.5M.
4D Molecular Therapeutics, Inc. (FDMT) was upgraded to D from D- on 11/11/2022 due to an increase in the growth index, total return index and volatility index. Total revenue increased 208.64% from $162 to $500, earnings per share increased from -$0.8689 to -$0.7933, and EBIT increased 6.79% from -$28.43M to -$26.5M.
D
Sell
8/15/2022Downgrade
4D Molecular Therapeutics, Inc. (FDMT) was downgraded to D- from D on 8/15/2022 due to a noticeable decline in the growth index, solvency index and volatility index. Total revenue declined 86.71% from $1.22M to $162, the quick ratio declined from 19.53 to 16.82, and EBIT declined 7.71% from -$26.39M to -$28.43M.
4D Molecular Therapeutics, Inc. (FDMT) was downgraded to D- from D on 8/15/2022 due to a noticeable decline in the growth index, solvency index and volatility index. Total revenue declined 86.71% from $1.22M to $162, the quick ratio declined from 19.53 to 16.82, and EBIT declined 7.71% from -$26.39M to -$28.43M.
D
Sell
5/16/2022Upgraded
4D Molecular Therapeutics, Inc. (FDMT) was upgraded to D from E+ on 05/16/2022.
4D Molecular Therapeutics, Inc. (FDMT) was upgraded to D from E+ on 05/16/2022.
E
Sell
5/13/2022Downgrade
4D Molecular Therapeutics, Inc. (FDMT) was downgraded to E+ from D on 5/13/2022 due to a decline in the solvency index and volatility index.
4D Molecular Therapeutics, Inc. (FDMT) was downgraded to E+ from D on 5/13/2022 due to a decline in the solvency index and volatility index.
D
Sell
5/4/2022Upgraded
4D Molecular Therapeutics, Inc. (FDMT) was upgraded to D from E+ on 05/04/2022.
4D Molecular Therapeutics, Inc. (FDMT) was upgraded to D from E+ on 05/04/2022.
E
Sell
5/1/2022Downgrade
4D Molecular Therapeutics, Inc. (FDMT) was downgraded to E+ from D on 5/1/2022 due to a decline in the total return index.
4D Molecular Therapeutics, Inc. (FDMT) was downgraded to E+ from D on 5/1/2022 due to a decline in the total return index.
D
Sell
4/21/2022Upgraded
4D Molecular Therapeutics, Inc. (FDMT) was upgraded to D from E+ on 4/21/2022 due to an increase in the valuation index.
4D Molecular Therapeutics, Inc. (FDMT) was upgraded to D from E+ on 4/21/2022 due to an increase in the valuation index.
E
Sell
4/20/2022Downgrade
4D Molecular Therapeutics, Inc. (FDMT) was downgraded to E+ from D on 4/20/2022 due to a decline in the volatility index and total return index.
4D Molecular Therapeutics, Inc. (FDMT) was downgraded to E+ from D on 4/20/2022 due to a decline in the volatility index and total return index.
D
Sell
3/29/2022Upgraded
4D Molecular Therapeutics, Inc. (FDMT) was upgraded to D from D- on 3/29/2022 due to an increase in the solvency index and valuation index. The quick ratio increased from 14.29 to 15.17.
4D Molecular Therapeutics, Inc. (FDMT) was upgraded to D from D- on 3/29/2022 due to an increase in the solvency index and valuation index. The quick ratio increased from 14.29 to 15.17.
D
Sell
11/8/2021Downgrade
4D Molecular Therapeutics, Inc. (FDMT) was downgraded to D- from D on 11/8/2021 due to a significant decline in the volatility index and valuation index.
4D Molecular Therapeutics, Inc. (FDMT) was downgraded to D- from D on 11/8/2021 due to a significant decline in the volatility index and valuation index.
D
Sell
3/10/2021None
4D Molecular Therapeutics, Inc. (FDMT) was downgraded to D from U on 03/10/2021.
4D Molecular Therapeutics, Inc. (FDMT) was downgraded to D from U on 03/10/2021.
NASDAQ
03/13/2025 4:00PM Eastern
Quotes delayed
